Clinical Trials
48 trialsPSMACare
Novartis
18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer
National Institutes of Health Clinical Center (CC)
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Multimodal Machine Learning Characterization of Solid Tumors
Massachusetts General Hospital
Prospective Monitoring of Subjects With Biochemically Recurrent Prostate Cancer Using 18FDCFPyL
National Institutes of Health Clinical Center (CC)
Focal Therapy With Stereotactic Body Radiation Therapy (SBRT) for Patients With a Single Prostate Tumor
National Institutes of Health Clinical Center (CC)
A Pilot Presurgical Trial of REGN5678 (Anti-PSMA x CD28) in Patients With High-risk, Localized Prostate Cancer Followed by Radical Prostatectomy
M.D. Anderson Cancer Center
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
National Institutes of Health Clinical Center (CC)
18F-DCFPyL PET/CT in High Risk and Recurrent Prostate Cancer
National Institutes of Health Clinical Center (CC)
18F-DCFPyL Imaging as a Method to Assess Treatment Response to Stereotactic Body Radiation Therapy
National Institutes of Health Clinical Center (CC)
A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer
M.D. Anderson Cancer Center
Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
High Resolution, 18F-PSMA PET-MRI Before Prostate Cancer HIFU or Radical Prostatectomy
Cedars-Sinai Medical Center
Image-guided Focal Brachytherapy Utilizing Combined 18F-DCFPyl PET/CT
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Evaluation of PSMA in HER2- AR+ Metastatic Breast Cancer
University of Wisconsin, Madison
Pilot of 18F-DCFPyL-PSMA PET in mCRPC Patients Receiving 117Lu-Vipivotide Tetraxetan
Brigham and Women's Hospital
RefleXion PET/CT Imaging Performance in Patients With Prostate Cancer
City of Hope Medical Center
HARRIER
Lantheus Medical Imaging
Evaluation of the Change in PSMA Expression in Prostate Cancer in Response to Hormonal Therapy
OHSU Knight Cancer Institute
PSMA-Targeted 18F-DCFPyL PET/MRI for the Detection of Prostate Cancer
Northwestern University
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Prostate SBRT for Locally Recurrent Prostate Cancer After Prior Radiotherapy
National Institutes of Health Clinical Center (CC)
MIRROR
Lantheus Medical Imaging
18F-DCFPyL PET/CT in Hepatocellular Carcinoma
National Institutes of Health Clinical Center (CC)
PSMA Therapy and Immunotherapy in Kidney Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
HepaSMART
Peter MacCallum Cancer Centre, Australia
Ultralow Dose PET Imaging for PSMA Expression
Nuclear Imaging Institute
PET/MRI for the Staging of Newly Diagnosed Prostate Cancer
Northwestern University
PROSPYL
VA Greater Los Angeles Healthcare System
Prostate MRI and Pylarify PSMA PET/CT
Corewell Health East
Head-to-head Comparison of [18F]AlF-PSMA-N5 With [18F]F-DCFPyL PET/CT in PCa Diagnosis, Recurrence, and Metastasis
Anhui Provincial Hospital
18F-DCFPyL PET/MRI in Regional Nodal&Distant Metastases Detection in Intermediate &HR Prostate Cancer
Stanford University
18F-DCFPyL Positron Emission Tomography (PET) in Intermediate or High Risk Prostate Cancer
University of Pittsburgh
Assessment of Multi-Modality Quantitative Imaging for Evaluation of Response of Metastatic Prostate Cancer to Therapy
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
PSMA PET Scan and mpMRI for Prostate Cancer Detection
VA Greater Los Angeles Healthcare System
PSMA-dRT
Jonsson Comprehensive Cancer Center
Targeted Imaging of Glutamate Carboxypeptidase II With DCFPyL-PET
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Prostate Cancer Monitoring Using [18F]DCFPyL and Blood Based Biomarkers
Columbia University
F18 DCFPyL PET/CT in Imaging Participants With Recurrent Prostate Cancer
Stanford University
Test-Retest Reproducibility of 18F-DCFPyL PET/CT in the Evaluation of Patients With Metastatic Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
OSPREY
Progenics Pharmaceuticals, Inc.
CONDOR
Progenics Pharmaceuticals, Inc.
Study of 18F-DCFPyL, a Second Generation Low-molecular Weight PSMA-based PET Radiotracer, in Patients With Prostate Cancer
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Evaluation of 18F-DCFPyL PSMA- Versus 18F-NaF-PET Imaging for Detection of Metastatic Prostate Cancer.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Study of PSMA-targeted 18F-DCFPyL PET/CT in the Evaluation of Patients With Renal Cell Carcinoma
Johns Hopkins University
18F-DCFPyL PET-CT Scan and Prostate Cancer
VA Greater Los Angeles Healthcare System
Integrated 18F-labelled PSMA Project
St. Joseph's Healthcare Hamilton